Abstract: Since 2019, SARS-CoV-2 has undergone mutations, resulting in pandemic and epidemic waves. The SARS-CoV-2 spike protein, crucial for cellular entry, binds to the ACE2 receptor exclusively when its receptor-binding domain (RBD) adopts the up-conformation. However, whether ACE2 also interacts with the RBD in the down-conformation to facilitate the conformational shift to RBD-up remains unclear. Herein, we present the structures of the BA.2.86 and the JN.1 spike proteins bound to ACE2. Notably, we successfully observed the ACE2-bound down-RBD, indicating an intermediate structure before the RBD-up conformation. The wider and mobile angle of RBDs in the up-state provides space for ACE2 to interact with the down-RBD, facilitating the transition to the RBD-up state. The K356T, but not N354-linked glycan, contributes to both of infectivity and neutralizing-antibody evasion in BA.2.86. These structural insights into spike-protein dynamics help explain the mechanisms underlying SARS-CoV-2 infection and its neutralization.
Introduction: The Evolution of Immune Evasion
The SARS-CoV-2 spike (S) protein is the primary target for neutralizing antibodies and the key mediator of viral entry via the human ACE2 receptor. A long-standing model of infection posits that the receptor-binding domain (RBD) must transition from a "down" (closed) state to an "up" (open) state to access the receptor. However, the emergence of highly mutated variants like BA.2.86 (Pirola) and its descendant JN.1 has challenged our understanding of this process. These variants have rapidly become dominant worldwide, demonstrating a remarkable ability to balance high infectivity with significant immune evasion.
Phylogenetic relationship and global detection frequency of SARS-CoV-2 variants, showing the rapid dominance of the JN.1 lineage.
Researchers utilized high-resolution cryo-electron microscopy (cryo-EM) to visualize the BA.2.86 and JN.1 spike proteins. Advanced computational techniques, including 3D Flexible Refinement (3DFlex), were used to map the inherent mobility of the RBDs. Binding kinetics were quantified using Surface Plasmon Resonance (SPR), and the functional consequences of specific mutations, such as K356T, were evaluated through pseudovirus entry assays and neutralization tests using human convalescent sera from XBB.1.5 breakthrough infections. The study integrated genomic data from GISAID and structural models deposited in the PDB (e.g., 8WXL, 8XUX).
Structural Insights: The "Catch-and-Pull" Mechanism
The study revealed that BA.2.86 and JN.1 utilize a novel "catch-and-pull" mechanism for cell entry. Cryo-EM snapshots captured a previously unobserved intermediate state: ACE2 bound to an RBD in the down-conformation. This suggests that ACE2 can initiate binding before the RBD is fully open, subsequently pulling it into the "up" state. This process is facilitated by the exceptionally wide opening angles of the BA.2.86 RBD (~111° compared to ~34° in earlier strains), which create sufficient space for ACE2 to engage the remaining closed RBDs on the spike trimer.
Summary of observed spike protein conformations across major Omicron subvariants, highlighting the unique structural landscape of BA.2.86.
A critical mutation, K356T, was found to enhance both infectivity and immune evasion. While this mutation creates a potential N-glycosylation site at N354, experimental results indicated that the amino acid substitution itself is the primary driver of these effects, rather than the addition of a glycan.
Key Results: Binding Affinity and Evasion
Biochemical assays demonstrated that BA.2.86 has a significantly higher affinity for ACE2 ($K_D = 0.74$ nM) than the earlier XBB.1.5 variant ($K_D = 2.22$ nM). Interestingly, JN.1 showed a moderate decrease in affinity ($K_D = 1.50$ nM) relative to BA.2.86, likely representing an evolutionary trade-off that prioritizes immune evasion once a sufficient binding threshold is met. Both variants exhibited substantial resistance to neutralization by XBB.1.5-induced antibodies, a finding corroborated by computational docking simulations showing that mutations like R403K and K356T disrupt key epitopes for known therapeutic antibodies.
Limitations and Future Directions
While these structural insights are profound, they are based on in vitro models. Real-world infection involves additional complexities, such as host proteases and co-receptors. The transient nature of the "down-bound" state, which is thermally unstable at physiological temperatures, presents challenges for therapeutic targeting. Future work will investigate if this "catch-and-pull" mechanism is a universal evolutionary trajectory for emerging variants and if it can be exploited to design broader-spectrum vaccines.
Summary updated
Abstract
Since 2019, SARS-CoV-2 has undergone mutations, resulting in pandemic and epidemic waves. The SARS-CoV-2 spike protein, crucial for cellular entry, binds to the ACE2 receptor exclusively when its receptor-binding domain (RBD) adopts the up-conformation. However, whether ACE2 also interacts with the RBD in the down-conformation to facilitate the conformational shift to RBD-up remains unclear. Herein, we present the structures of the BA.2.86 and the JN.1 spike proteins bound to ACE2. Notably, we successfully observed the ACE2-bound down-RBD, indicating an intermediate structure before the RBD-up conformation. The wider and mobile angle of RBDs in the up-state provides space for ACE2 to interact with the down-RBD, facilitating the transition to the RBD-up state. The K356T, but not N354-linked glycan, contributes to both of infectivity and neutralizing-antibody evasion in BA.2.86. These structural insights the spike-protein dynamics would help understand the mechanisms underlying SARS-CoV-2 infection and its neutralization.
BibTeX
@inproceedings{yajima2024structural,
author = {Hisano Yajima and Yuki Anraku and Yu Kaku and Kanako Kimura and Arnon Plianchaisuk and Kaho Okumura and Yoshiko Nakada-Nakura and Yusuke Atarashi and Takuya Hemmi and Daisuke Kuroda and Yoshimasa Takahashi and Shunsuke Kita and Jiei Sasaki and Hiromi Sumita and Keita Matsuno and Naganori Nao and Hirofumi Sawa and Keita Mizuma and Jingshu Li and Izumi Kida and Yume Mimura and Yuma Ohari and Shinya Tanaka and Masumi Tsuda and Lei Wang and Yoshikata Oda and Zannatul Ferdous and Kenji Shishido and Hiromi Mohri and Miki Iida and Takasuke Fukuhara and Tomokazu Tamura and Rigel Suzuki and Saori Suzuki and Shuhei Tsujino and Hayato Ito and Naoko Misawa and Ziyi Guo and Alfredo A. Hinay and Kaoru Usui and Wilaiporn Saikruang and Spyridon Lytras and Keiya Uriu and Ryo Yoshimura and Shusuke Kawakubo and Luca Nishumura and Yusuke Kosugi and Shigeru Fujita and Jarel Elgin Tolentino and Chen Luo and Lin Pan and Wenye Li and Maximilian Stanley Yo and Kio Horinaka and Mai Suganami and Mika Chiba and Kyoko Yasuda and Keiko Iida and Adam Strange and Naomi Ohsumi and Shiho Tanaka and E. Ogawa and T Fukuda and Rina Osujo and Kazuhisa Yoshimura and Kenji Sadamas and Mami Nagashima and Hiroyuki Asakura and Isao Yoshida and So Nakagawa and Kazuo Takayama and Rina Hashimoto and Sayaka Deguchi and Yukio Watanabe and Yoshitaka Nakata and Hiroki Futatsusako and Ayaka Sakamoto and Naoko Yasuhara and Tateki Suzuki and Yukari Nakajima and Takashi Irie and Ryoko Kawabata and Kaori Sasaki‐Tabata and Terumasa Ikeda and Hesham Nasser and Ryo Shimizu and M. S. T. Monira Begum and Michael Jonathan and Yuka Mugita and Sharee Leong and Otowa Takahashi and Takamasa Ueno and Chihiro Motozono and Mako Toyoda and Akatsuki Saito and Anon Kosaka and Miki Kawano and N Matsubara and Tomoko Nishiuchi and Jiří Zahradník},
title = {{Structural basis for receptor-binding domain mobility of the spike in SARS-CoV-2 BA.2.86 and JN.1}},
booktitle = {Nature Communications},
year = {2024},
doi = {10.1038/s41467-024-52808-2},
}